AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More
Tag: ASCEND
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
